Safety Study of PLX4032 in Patients With Solid Tumors

ABSTRACT: The primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors. The secondary objective is to assess the pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant melanoma who have the V600E BRAF oncogenic mutation.

DISEASE(S): Colorectal Carcinoma,Melanoma,Colorectal Neoplasms,Malignant Melanoma

PROVIDER: 2034890 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR